Febuxostat for conservatively managed intracranial hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial evaluates the effect of febuxostat 40 mg alongside standard medical care in adults with conservatively managed intracranial hemorrhage. Participants will be assessed for clinical outcomes and biomarkers of oxidative stress and inflammation to see if febuxostat can help reduce secondary brain injury. The study targets patients identified by CT imaging and managed according to clinical guidelines, with informed consent obtained from the patient or a legal representative. Primary safety and exploratory efficacy signals will guide future research on uric acid modulation in this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Age ≥ 18 years old.

  * Diagnosed with intracranial hemorrhage confirmed by CT scan.
  * Managed conservatively regarding clinical guidelines.
  * Able to provide informed consent or have a legal representative provide consent.

Exclusion Criteria:

* • Patients with a history of previous brain surgery or significant neurological disorders.

  * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease).
  * Allergy or contraindication to febuxostat.
  * Pregnant or breastfeeding women.
  * Patients requiring surgical intervention for hematoma evacuation.
  * Renal impairment with SCr \> 4
  * Liver impairment with INR \> 5
  * Significant deterioration ( GCS \< 8 )

Where it's running

• Neurosurgery department Mansoura university hospitals
  Al Mansurah, Dakahlia Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Mertihan E Elhadidi
• Email: Merihanelhadidy9@gmail.com
• Phone: +201124955511

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Atorvastatin for primary intracerebral hemorrhage

  This trial will see if adding atorvastatin to usual care helps adults (18–80) who have a spontaneous intracerebral hemorrhage and are treated within 3–24 hours of symptom onset.

  Recruiting at 22 sites The Second Hospital of Anhui Medical University · Anqing, Anhui and 21 other locations · NCT07088250

• IRRAflow continuous irrigation to clear blood and infection inside the head

  This trial tests whether the IRRAflow system, which continuously irrigates and drains the brain, clears intracranial blood and treats ventriculitis or abscess better than standard external ventricular drains in adults.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT06649097

• Oral N-Acetylcysteine for Diabetic Macular Edema

  This study tests whether taking N-acetylcysteine by mouth can help people with center-involving diabetic macular edema who don’t yet need anti-VEGF therapy.

  Recruiting Phase 2 Tanta University · Damietta · NCT07917338

• 3D-Printed versus Conventional Palatal Cribs for Tongue Thrust in Children

  This study tests whether a 3D-printed cobalt-chromium palatal crib works better than a traditional soldered stainless steel crib to help kids stop tongue thrusting.

  Recruiting Tanta University · Tanta · NCT07895121

• Dia-Root Bio MTA vs MTA Plus forIndirect Pulp Capping in Young Permanent Molars

  This trial tests whether Dia-Root Bio MTA works as an indirect pulp cap in kids’ first permanent molars better or similar to standard MTA Plus.

  Recruiting Tanta University · Tanta · NCT07894523

• Nanohydroxyapatite vs Fluoride Varnish for MIH Front Teeth

  This trial tests whether a nanohydroxyapatite varnish can remineralize MIH-affected front teeth in 8–11 year-olds as effectively as a standard 5% fluoride varnish.

  Recruiting Tanta University · Tanta · NCT07894510

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.